Copyright Reports & Markets. All rights reserved.

Global Non-steroidal Androgen Receptor Inhibitors（NSARIs） Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Non-steroidal Androgen Receptor Inhibitors（NSARIs） Consumption Value by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Enzalutamide
    • 1.3.3 Apalutamide
    • 1.3.4 Darolutamide
    • 1.3.5 Bicalutamide
    • 1.3.6 Nilutamide
  • 1.4 Market Analysis by Molecular
    • 1.4.1 Overview: Global Non-steroidal Androgen Receptor Inhibitors（NSARIs） Consumption Value by Molecular: 2021 Versus 2025 Versus 2032
    • 1.4.2 High BBB Penetration
    • 1.4.3 Low BBB Penetration
  • 1.5 Market Analysis by Application
    • 1.5.1 Overview: Global Non-steroidal Androgen Receptor Inhibitors（NSARIs） Consumption Value by Application: 2021 Versus 2025 Versus 2032
    • 1.5.2 nmCRPC
    • 1.5.3 mCRPC
    • 1.5.4 mHSPC
    • 1.5.5 Others
  • 1.6 Global Non-steroidal Androgen Receptor Inhibitors（NSARIs） Market Size & Forecast
    • 1.6.1 Global Non-steroidal Androgen Receptor Inhibitors（NSARIs） Consumption Value (2021 & 2025 & 2032)
    • 1.6.2 Global Non-steroidal Androgen Receptor Inhibitors（NSARIs） Sales Quantity (2021-2032)
    • 1.6.3 Global Non-steroidal Androgen Receptor Inhibitors（NSARIs） Average Price (2021-2032)

2 Manufacturers Profiles

  • 2.1 Astellas Pharma
    • 2.1.1 Astellas Pharma Details
    • 2.1.2 Astellas Pharma Major Business
    • 2.1.3 Astellas Pharma Non-steroidal Androgen Receptor Inhibitors（NSARIs） Product and Services
    • 2.1.4 Astellas Pharma Non-steroidal Androgen Receptor Inhibitors（NSARIs） Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Astellas Pharma Recent Developments/Updates
  • 2.2 Pfizer
    • 2.2.1 Pfizer Details
    • 2.2.2 Pfizer Major Business
    • 2.2.3 Pfizer Non-steroidal Androgen Receptor Inhibitors（NSARIs） Product and Services
    • 2.2.4 Pfizer Non-steroidal Androgen Receptor Inhibitors（NSARIs） Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Pfizer Recent Developments/Updates
  • 2.3 Johnson & Johnson
    • 2.3.1 Johnson & Johnson Details
    • 2.3.2 Johnson & Johnson Major Business
    • 2.3.3 Johnson & Johnson Non-steroidal Androgen Receptor Inhibitors（NSARIs） Product and Services
    • 2.3.4 Johnson & Johnson Non-steroidal Androgen Receptor Inhibitors（NSARIs） Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Johnson & Johnson Recent Developments/Updates
  • 2.4 Bayer AG
    • 2.4.1 Bayer AG Details
    • 2.4.2 Bayer AG Major Business
    • 2.4.3 Bayer AG Non-steroidal Androgen Receptor Inhibitors（NSARIs） Product and Services
    • 2.4.4 Bayer AG Non-steroidal Androgen Receptor Inhibitors（NSARIs） Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Bayer AG Recent Developments/Updates
  • 2.5 Orion
    • 2.5.1 Orion Details
    • 2.5.2 Orion Major Business
    • 2.5.3 Orion Non-steroidal Androgen Receptor Inhibitors（NSARIs） Product and Services
    • 2.5.4 Orion Non-steroidal Androgen Receptor Inhibitors（NSARIs） Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 Orion Recent Developments/Updates
  • 2.6 Lonza Group
    • 2.6.1 Lonza Group Details
    • 2.6.2 Lonza Group Major Business
    • 2.6.3 Lonza Group Non-steroidal Androgen Receptor Inhibitors（NSARIs） Product and Services
    • 2.6.4 Lonza Group Non-steroidal Androgen Receptor Inhibitors（NSARIs） Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 Lonza Group Recent Developments/Updates
  • 2.7 Catalent
    • 2.7.1 Catalent Details
    • 2.7.2 Catalent Major Business
    • 2.7.3 Catalent Non-steroidal Androgen Receptor Inhibitors（NSARIs） Product and Services
    • 2.7.4 Catalent Non-steroidal Androgen Receptor Inhibitors（NSARIs） Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 Catalent Recent Developments/Updates
  • 2.8 WuXi AppTec
    • 2.8.1 WuXi AppTec Details
    • 2.8.2 WuXi AppTec Major Business
    • 2.8.3 WuXi AppTec Non-steroidal Androgen Receptor Inhibitors（NSARIs） Product and Services
    • 2.8.4 WuXi AppTec Non-steroidal Androgen Receptor Inhibitors（NSARIs） Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 WuXi AppTec Recent Developments/Updates
  • 2.9 Asymchem Laboratories
    • 2.9.1 Asymchem Laboratories Details
    • 2.9.2 Asymchem Laboratories Major Business
    • 2.9.3 Asymchem Laboratories Non-steroidal Androgen Receptor Inhibitors（NSARIs） Product and Services
    • 2.9.4 Asymchem Laboratories Non-steroidal Androgen Receptor Inhibitors（NSARIs） Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 Asymchem Laboratories Recent Developments/Updates
  • 2.10 Recipharm
    • 2.10.1 Recipharm Details
    • 2.10.2 Recipharm Major Business
    • 2.10.3 Recipharm Non-steroidal Androgen Receptor Inhibitors（NSARIs） Product and Services
    • 2.10.4 Recipharm Non-steroidal Androgen Receptor Inhibitors（NSARIs） Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.10.5 Recipharm Recent Developments/Updates

3 Competitive Environment: Non-steroidal Androgen Receptor Inhibitors（NSARIs） by Manufacturer

  • 3.1 Global Non-steroidal Androgen Receptor Inhibitors（NSARIs） Sales Quantity by Manufacturer (2021-2026)
  • 3.2 Global Non-steroidal Androgen Receptor Inhibitors（NSARIs） Revenue by Manufacturer (2021-2026)
  • 3.3 Global Non-steroidal Androgen Receptor Inhibitors（NSARIs） Average Price by Manufacturer (2021-2026)
  • 3.4 Market Share Analysis (2025)
    • 3.4.1 Producer Shipments of Non-steroidal Androgen Receptor Inhibitors（NSARIs） by Manufacturer Revenue ($MM) and Market Share (%): 2025
    • 3.4.2 Top 3 Non-steroidal Androgen Receptor Inhibitors（NSARIs） Manufacturer Market Share in 2025
    • 3.4.3 Top 6 Non-steroidal Androgen Receptor Inhibitors（NSARIs） Manufacturer Market Share in 2025
  • 3.5 Non-steroidal Androgen Receptor Inhibitors（NSARIs） Market: Overall Company Footprint Analysis
    • 3.5.1 Non-steroidal Androgen Receptor Inhibitors（NSARIs） Market: Region Footprint
    • 3.5.2 Non-steroidal Androgen Receptor Inhibitors（NSARIs） Market: Company Product Type Footprint
    • 3.5.3 Non-steroidal Androgen Receptor Inhibitors（NSARIs） Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Non-steroidal Androgen Receptor Inhibitors（NSARIs） Market Size by Region
    • 4.1.1 Global Non-steroidal Androgen Receptor Inhibitors（NSARIs） Sales Quantity by Region (2021-2032)
    • 4.1.2 Global Non-steroidal Androgen Receptor Inhibitors（NSARIs） Consumption Value by Region (2021-2032)
    • 4.1.3 Global Non-steroidal Androgen Receptor Inhibitors（NSARIs） Average Price by Region (2021-2032)
  • 4.2 North America Non-steroidal Androgen Receptor Inhibitors（NSARIs） Consumption Value (2021-2032)
  • 4.3 Europe Non-steroidal Androgen Receptor Inhibitors（NSARIs） Consumption Value (2021-2032)
  • 4.4 Asia-Pacific Non-steroidal Androgen Receptor Inhibitors（NSARIs） Consumption Value (2021-2032)
  • 4.5 South America Non-steroidal Androgen Receptor Inhibitors（NSARIs） Consumption Value (2021-2032)
  • 4.6 Middle East & Africa Non-steroidal Androgen Receptor Inhibitors（NSARIs） Consumption Value (2021-2032)

5 Market Segment by Type

  • 5.1 Global Non-steroidal Androgen Receptor Inhibitors（NSARIs） Sales Quantity by Type (2021-2032)
  • 5.2 Global Non-steroidal Androgen Receptor Inhibitors（NSARIs） Consumption Value by Type (2021-2032)
  • 5.3 Global Non-steroidal Androgen Receptor Inhibitors（NSARIs） Average Price by Type (2021-2032)

6 Market Segment by Application

  • 6.1 Global Non-steroidal Androgen Receptor Inhibitors（NSARIs） Sales Quantity by Application (2021-2032)
  • 6.2 Global Non-steroidal Androgen Receptor Inhibitors（NSARIs） Consumption Value by Application (2021-2032)
  • 6.3 Global Non-steroidal Androgen Receptor Inhibitors（NSARIs） Average Price by Application (2021-2032)

7 North America

  • 7.1 North America Non-steroidal Androgen Receptor Inhibitors（NSARIs） Sales Quantity by Type (2021-2032)
  • 7.2 North America Non-steroidal Androgen Receptor Inhibitors（NSARIs） Sales Quantity by Application (2021-2032)
  • 7.3 North America Non-steroidal Androgen Receptor Inhibitors（NSARIs） Market Size by Country
    • 7.3.1 North America Non-steroidal Androgen Receptor Inhibitors（NSARIs） Sales Quantity by Country (2021-2032)
    • 7.3.2 North America Non-steroidal Androgen Receptor Inhibitors（NSARIs） Consumption Value by Country (2021-2032)
    • 7.3.3 United States Market Size and Forecast (2021-2032)
    • 7.3.4 Canada Market Size and Forecast (2021-2032)
    • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

  • 8.1 Europe Non-steroidal Androgen Receptor Inhibitors（NSARIs） Sales Quantity by Type (2021-2032)
  • 8.2 Europe Non-steroidal Androgen Receptor Inhibitors（NSARIs） Sales Quantity by Application (2021-2032)
  • 8.3 Europe Non-steroidal Androgen Receptor Inhibitors（NSARIs） Market Size by Country
    • 8.3.1 Europe Non-steroidal Androgen Receptor Inhibitors（NSARIs） Sales Quantity by Country (2021-2032)
    • 8.3.2 Europe Non-steroidal Androgen Receptor Inhibitors（NSARIs） Consumption Value by Country (2021-2032)
    • 8.3.3 Germany Market Size and Forecast (2021-2032)
    • 8.3.4 France Market Size and Forecast (2021-2032)
    • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
    • 8.3.6 Russia Market Size and Forecast (2021-2032)
    • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

  • 9.1 Asia-Pacific Non-steroidal Androgen Receptor Inhibitors（NSARIs） Sales Quantity by Type (2021-2032)
  • 9.2 Asia-Pacific Non-steroidal Androgen Receptor Inhibitors（NSARIs） Sales Quantity by Application (2021-2032)
  • 9.3 Asia-Pacific Non-steroidal Androgen Receptor Inhibitors（NSARIs） Market Size by Region
    • 9.3.1 Asia-Pacific Non-steroidal Androgen Receptor Inhibitors（NSARIs） Sales Quantity by Region (2021-2032)
    • 9.3.2 Asia-Pacific Non-steroidal Androgen Receptor Inhibitors（NSARIs） Consumption Value by Region (2021-2032)
    • 9.3.3 China Market Size and Forecast (2021-2032)
    • 9.3.4 Japan Market Size and Forecast (2021-2032)
    • 9.3.5 South Korea Market Size and Forecast (2021-2032)
    • 9.3.6 India Market Size and Forecast (2021-2032)
    • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
    • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

  • 10.1 South America Non-steroidal Androgen Receptor Inhibitors（NSARIs） Sales Quantity by Type (2021-2032)
  • 10.2 South America Non-steroidal Androgen Receptor Inhibitors（NSARIs） Sales Quantity by Application (2021-2032)
  • 10.3 South America Non-steroidal Androgen Receptor Inhibitors（NSARIs） Market Size by Country
    • 10.3.1 South America Non-steroidal Androgen Receptor Inhibitors（NSARIs） Sales Quantity by Country (2021-2032)
    • 10.3.2 South America Non-steroidal Androgen Receptor Inhibitors（NSARIs） Consumption Value by Country (2021-2032)
    • 10.3.3 Brazil Market Size and Forecast (2021-2032)
    • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

  • 11.1 Middle East & Africa Non-steroidal Androgen Receptor Inhibitors（NSARIs） Sales Quantity by Type (2021-2032)
  • 11.2 Middle East & Africa Non-steroidal Androgen Receptor Inhibitors（NSARIs） Sales Quantity by Application (2021-2032)
  • 11.3 Middle East & Africa Non-steroidal Androgen Receptor Inhibitors（NSARIs） Market Size by Country
    • 11.3.1 Middle East & Africa Non-steroidal Androgen Receptor Inhibitors（NSARIs） Sales Quantity by Country (2021-2032)
    • 11.3.2 Middle East & Africa Non-steroidal Androgen Receptor Inhibitors（NSARIs） Consumption Value by Country (2021-2032)
    • 11.3.3 Turkey Market Size and Forecast (2021-2032)
    • 11.3.4 Egypt Market Size and Forecast (2021-2032)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
    • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

  • 12.1 Non-steroidal Androgen Receptor Inhibitors（NSARIs） Market Drivers
  • 12.2 Non-steroidal Androgen Receptor Inhibitors（NSARIs） Market Restraints
  • 12.3 Non-steroidal Androgen Receptor Inhibitors（NSARIs） Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Non-steroidal Androgen Receptor Inhibitors（NSARIs） and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Non-steroidal Androgen Receptor Inhibitors（NSARIs）
  • 13.3 Non-steroidal Androgen Receptor Inhibitors（NSARIs） Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Non-steroidal Androgen Receptor Inhibitors（NSARIs） Typical Distributors
  • 14.3 Non-steroidal Androgen Receptor Inhibitors（NSARIs） Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Non-steroidal Androgen Receptor Inhibitors（NSARIs） market size was valued at US$ 4983 million in 2025 and is forecast to a readjusted size of US$ 18278 million by 2032 with a CAGR of 20.4% during review period.
    Non-steroidal androgen receptor inhibitors (NSARIs) are a class of oral small-molecule drugs that competitively bind to the androgen receptor (AR), inhibiting its nuclear translocation and transcriptional activity without possessing a steroidal structure; they selectively block androgen signaling pathways that drive prostate cancer progression and represent a core component of endocrine therapy for prostate cancer; the class has evolved from first-generation agents (e.g., bicalutamide) to second-generation high-affinity inhibitors such as Enzalutamide, Apalutamide, and Darolutamide, with continuous improvements in efficacy, resistance management, and safety profile, primarily indicated for nmCRPC and mHSPC and typically used in combination with androgen deprivation therapy (ADT).The global market for non-steroidal androgen receptor inhibitors is estimated at USD 4.8 billion in 2025, with a projected CAGR of approximately 20.85% from 2025 to 2030, corresponding to an annual treated patient population of about 500,000–600,000, driven by increasing penetration in nmCRPC, mCRPC, and mHSPC. Nominal capacity from the global high-potency small-molecule API network is sufficient to meet demand, and capacity does not constitute a constraint. Average treatment cost per patient per year is approximately USD 90,000–100,000 in the U.S., USD 50,000–70,000 in Europe, and USD 15,000–20,000 in China post-reimbursement negotiations, resulting in a weighted average of about USD 65,000 per patient per year, with a blended gross margin of roughly 85–90%.
    Downstream demand is concentrated in the prostate cancer treatment pathway within oncology (nmCRPC → mCRPC → mHSPC). The value chain upstream consists of high-potency APIs and key intermediates synthesized via multi-step heterocyclic processes; midstream commercialization is led by originator companies (Astellas Pharma Inc., Pfizer Inc., Johnson & Johnson, and Bayer AG/Orion Corporation); downstream channels consist of hospitals and oncology specialty clinics. The global industry structure is characterized by “originator oligopoly + guideline-driven adoption + patent protection,” with primary competition from Enzalutamide, Apalutamide, and Darolutamide. The core compound patent of Darolutamide is expected to expire around 2030, but indication, formulation, and regional patent extensions may prolong actual market exclusivity to 2032–2035. Overall, the market is in the late growth stage, driven primarily by indication expansion and an increasing aging patient population, with key uncertainty arising from post-patent generic entry and reimbursement pressure.
    This report is a detailed and comprehensive analysis for global Non-steroidal Androgen Receptor Inhibitors（NSARIs） market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Non-steroidal Androgen Receptor Inhibitors（NSARIs） market size and forecasts, in consumption value ($ Million), sales quantity (Tons), and average selling prices (US$/Ton), 2021-2032
    Global Non-steroidal Androgen Receptor Inhibitors（NSARIs） market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Tons), and average selling prices (US$/Ton), 2021-2032
    Global Non-steroidal Androgen Receptor Inhibitors（NSARIs） market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Tons), and average selling prices (US$/Ton), 2021-2032
    Global Non-steroidal Androgen Receptor Inhibitors（NSARIs） market shares of main players, shipments in revenue ($ Million), sales quantity (Tons), and ASP (US$/Ton), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Non-steroidal Androgen Receptor Inhibitors（NSARIs）
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Non-steroidal Androgen Receptor Inhibitors（NSARIs） market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Astellas Pharma, Pfizer, Johnson & Johnson, Bayer AG, Orion, Lonza Group, Catalent, WuXi AppTec, Asymchem Laboratories, Recipharm, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market Segmentation
    Non-steroidal Androgen Receptor Inhibitors（NSARIs） market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Enzalutamide
    Apalutamide
    Darolutamide
    Bicalutamide
    Nilutamide
    Market segment by Molecular
    High BBB Penetration
    Low BBB Penetration
    Market segment by Application
    nmCRPC
    mCRPC
    mHSPC
    Others
    Major players covered
    Astellas Pharma
    Pfizer
    Johnson & Johnson
    Bayer AG
    Orion
    Lonza Group
    Catalent
    WuXi AppTec
    Asymchem Laboratories
    Recipharm
    Market segment by region, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 15 chapters:
    Chapter 1, to describe Non-steroidal Androgen Receptor Inhibitors（NSARIs） product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of Non-steroidal Androgen Receptor Inhibitors（NSARIs）, with price, sales quantity, revenue, and global market share of Non-steroidal Androgen Receptor Inhibitors（NSARIs） from 2021 to 2026.
    Chapter 3, the Non-steroidal Androgen Receptor Inhibitors（NSARIs） competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the Non-steroidal Androgen Receptor Inhibitors（NSARIs） breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
    Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Non-steroidal Androgen Receptor Inhibitors（NSARIs） market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
    Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
    Chapter 13, the key raw materials and key suppliers, and industry chain of Non-steroidal Androgen Receptor Inhibitors（NSARIs）.
    Chapter 14 and 15, to describe Non-steroidal Androgen Receptor Inhibitors（NSARIs） sales channel, distributors, customers, research findings and conclusion.

    Buy now